Novo NordiskNVO stock slumped Wednesday after the drugmaker said it expects continued competition this year from "unsafe and ...

The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according ...

This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a higher risk of muscle loss and reduced mobility.

Once aimed at diabetes patients, drugs like Ozempic are famous for bringing about rapid weight loss. But the injections often ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Levi & Korsinsky is representing the shareholder plaintiff in a suit claiming the Ozempic and Wegovy manufacturer withheld ...

Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain ...

It’s the most high-profile example yet of a controversial industry practice called preferred pharmacy networks, or PPNs ...